Presentation is loading. Please wait.

Presentation is loading. Please wait.

Tina Cascone, MD, PhD, Kathryn A. Gold, MD, Stephen G

Published byHartono Sanjaya Modified over 6 years ago

Similar presentations

Presentation on theme: "Tina Cascone, MD, PhD, Kathryn A. Gold, MD, Stephen G"— Presentation transcript:

1 Induction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung Cancer 
Tina Cascone, MD, PhD, Kathryn A. Gold, MD, Stephen G. Swisher, MD, Diane D. Liu, MS, Frank V. Fossella, MD, Boris Sepesi, MD, Apar Pataer, MD, Annikka Weissferdt, MD, Neda Kalhor, MD, Ara A. Vaporciyan, MD, Wayne L. Hofstetter, MD, Ignacio I. Wistuba, MD, John V. Heymach, MD, PhD, Edward S. Kim, MD, William N. William, MD  The Annals of Thoracic Surgery  Volume 105, Issue 2, Pages (February 2018) DOI: /j.athoracsur Copyright © 2018 The Society of Thoracic Surgeons Terms and Conditions

2 Fig 1 Overall survival by stage in whole study population. (E = number of events; N = number of patients; OS = overall survival.) The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2018 The Society of Thoracic Surgeons Terms and Conditions

3 Fig 2 Disease-free survival according to response by imaging studies (A), mediastinal downstaging (B), pathologic complete mediastinal and nodal response (C), or major pathologic response (D). DFS = disease-free survival; E = number of events; MPR = major pathologic response; N = number of patients; PR = partial response; SD = stable disease. The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2018 The Society of Thoracic Surgeons Terms and Conditions

4 Fig 3 Overall survival according to response by imaging studies (A), mediastinal downstaging (B), pathologic complete mediastinal and nodal response (C), or major pathologic response (D). E = number of events; MPR = major pathologic response; N = number of patients; OS = overall survival; PR = partial response; SD = stable disease. The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2018 The Society of Thoracic Surgeons Terms and Conditions

5 Supplemental Fig S1 The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2018 The Society of Thoracic Surgeons Terms and Conditions

6 Supplemental Fig S2 The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2018 The Society of Thoracic Surgeons Terms and Conditions

7 Supplemental Fig S3 The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2018 The Society of Thoracic Surgeons Terms and Conditions

Download ppt "Tina Cascone, MD, PhD, Kathryn A. Gold, MD, Stephen G"

Similar presentations

Jeffrey M. Griffin, MD, MS, Carolyn E. Reed, MD, Chadrick E

Jeffrey M. Griffin, MD, MS, Carolyn E. Reed, MD, Chadrick E
Jeffrey L. Port, MD, Robert J. Korst, MD, Paul C. Lee, MD, Amanda L

Jeffrey L. Port, MD, Robert J. Korst, MD, Paul C. Lee, MD, Amanda L
A Propensity-Matched Analysis of Wedge Resection and Stereotactic Body Radiotherapy for Early Stage Lung Cancer  Jeffrey L. Port, MD, Bhupesh Parashar,

A Propensity-Matched Analysis of Wedge Resection and Stereotactic Body Radiotherapy for Early Stage Lung Cancer  Jeffrey L. Port, MD, Bhupesh Parashar,
Survival After Surgical Resection for Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease  Anders Bugge, MD, May Brit Lund, MD, PhD, Cathrine.

Survival After Surgical Resection for Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease  Anders Bugge, MD, May Brit Lund, MD, PhD, Cathrine.
Complete Thoracic Mediastinal Lymphadenectomy Leads to a Higher Rate of Pathologically Proven N2 Disease in Patients With Non-Small Cell Lung Cancer 

Complete Thoracic Mediastinal Lymphadenectomy Leads to a Higher Rate of Pathologically Proven N2 Disease in Patients With Non-Small Cell Lung Cancer 
Thomas J. Birdas, MD, Richard P. M

Thomas J. Birdas, MD, Richard P. M
Preoperative Serum Fibrinogen Level Predicts Postoperative Pulmonary Complications After Lung Cancer Resection  Suk-Won Song, MD, Hyun-Sung Lee, MD, Moon.

Preoperative Serum Fibrinogen Level Predicts Postoperative Pulmonary Complications After Lung Cancer Resection  Suk-Won Song, MD, Hyun-Sung Lee, MD, Moon.
Melanie Subramanian, MD, Timothy McMurry, PhD, Bryan F

Melanie Subramanian, MD, Timothy McMurry, PhD, Bryan F
Evaluation of the Reliability of Clinical Staging of T2 N0 Esophageal Cancer: A Review of The Society of Thoracic Surgeons Database  Traves D. Crabtree,

Evaluation of the Reliability of Clinical Staging of T2 N0 Esophageal Cancer: A Review of The Society of Thoracic Surgeons Database  Traves D. Crabtree,
Comparison of Thoracoscopic Segmentectomy and Thoracoscopic Lobectomy for Small-Sized Stage IA Lung Cancer  Chenxi Zhong, MD, Wentao Fang, MD, Teng Mao,

Comparison of Thoracoscopic Segmentectomy and Thoracoscopic Lobectomy for Small-Sized Stage IA Lung Cancer  Chenxi Zhong, MD, Wentao Fang, MD, Teng Mao,
Joshua E. Rosen, BASc, Hari B

Joshua E. Rosen, BASc, Hari B
Sarcomatoid Carcinoma of the Lung: A Predictor of Poor Prognosis

Sarcomatoid Carcinoma of the Lung: A Predictor of Poor Prognosis
Tumor Necrosis as a Prognostic Factor for Stage IA Non-Small Cell Lung Cancer  Seong Yong Park, MD, Hyun-Sung Lee, MD, PhD, Hee-Jin Jang, MD, Geon Kook.

Tumor Necrosis as a Prognostic Factor for Stage IA Non-Small Cell Lung Cancer  Seong Yong Park, MD, Hyun-Sung Lee, MD, PhD, Hee-Jin Jang, MD, Geon Kook.
Puja Gaur, MD, Wayne L. Hofstetter, MD, B

Puja Gaur, MD, Wayne L. Hofstetter, MD, B
Long-Term Outcome After Resection of Non-Small Cell Lung Cancer Invading the Thoracic Inlet  Stéphane Collaud, MD, MS, Tiago Machuca, MD, PhD, Olaf Mercier,

Long-Term Outcome After Resection of Non-Small Cell Lung Cancer Invading the Thoracic Inlet  Stéphane Collaud, MD, MS, Tiago Machuca, MD, PhD, Olaf Mercier,
Morbidity, Survival, and Site of Recurrence After Mediastinal Lymph-Node Dissection Versus Systematic Sampling After Complete Resection for Non-Small.

Morbidity, Survival, and Site of Recurrence After Mediastinal Lymph-Node Dissection Versus Systematic Sampling After Complete Resection for Non-Small.
Benjamin E. Lee, MD, Mark Shapiro, MD, John R. Rutledge, MAS, Robert J

Benjamin E. Lee, MD, Mark Shapiro, MD, John R. Rutledge, MAS, Robert J
Osteopontin Combined With CD44v6, a Novel Prognostic Biomarker in Non-Small Cell Lung Cancer Undergoing Curative Resection  Bing-sheng Sun, MD, PhD, Yue.

Osteopontin Combined With CD44v6, a Novel Prognostic Biomarker in Non-Small Cell Lung Cancer Undergoing Curative Resection  Bing-sheng Sun, MD, PhD, Yue.
Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy  Apar Pataer, MD, PhD, Neda Kalhor,

Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy  Apar Pataer, MD, PhD, Neda Kalhor,
Video-Assisted Thoracic Surgery Lobectomy: Experience With 1,100 Cases

Video-Assisted Thoracic Surgery Lobectomy: Experience With 1,100 Cases

Similar presentations

Ads by Google